Overview

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Status:
Active, not recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

The main goal of this study is to estimate the tumor response rate of temozolomide administered in combination with peginterferon alfa-2b to pediatric patients with unresectable Stage III, metastatic, or recurrent cutaneous melanoma.

Phase:

Phase 2

Details

Lead Sponsor:

St. Jude Children's Research Hospital

Collaborator:

Schering-Plough

Treatments:

Antineoplastic Agents
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2b
Temozolomide